Disc Medicine, Inc. (IRON)
| Market Cap | 3.31B +10.4% |
| Revenue (ttm) | n/a |
| Net Income | -245.89M |
| EPS | -6.56 |
| Shares Out | 44.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,963,017 |
| Open | 74.29 |
| Previous Close | 75.03 |
| Day's Range | 74.01 - 75.56 |
| 52-Week Range | 40.00 - 99.50 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 103.17 (+38.47%) |
| Est. Earnings | Nov 5, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $103.17, which is an increase of 38.47% from the latest price.
News
Disc Medicine price target raised to $110 from $100 at Wedbush
Wedbush raised the firm’s price target on Disc Medicine (IRON) to $110 from $100 and keeps an Outperform rating on the shares. The firm notes the company reported positive topline…
Disc Medicine 6M share Secondary priced at $75.00
The deal size was increased to $450M from $350M and priced below last closing price of $79.48. Jefferies, Leerink, Morgan Stanley and Cantor Fitzgerald are acting as joint book running…
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine price target raised to $115 from $83 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Disc Medicine (IRON) to $115 from $83 and keeps a Buy rating on the shares. The firm states that it…
Disc Medicine price target raised to $92 from $90 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $92 from $90 and keeps an Overweight rating on the shares.
Disc Medicine price target raised to $170 from $125 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Disc Medicine (IRON) to $170 from $125 and keeps an Overweight rating on the shares. Disc Medicine reported positive Phase 3 APOLLO…
Disc Medicine price target raised to $124 from $86 at Wells Fargo
Wells Fargo raised the firm’s price target on Disc Medicine (IRON) to $124 from $86 and keeps an Overweight rating on the shares. The firm is raising bitopertin’s approval odds…
Disc Medicine announces $350M common stock, warrants offering
Disc Medicine (IRON) announced the commencement of an underwritten public offering of $350M of shares of its common stock and, in lieu of common stock to certain investors that so…
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine price target raised to $115 from $83 at Truist
Truist raised the firm’s price target on Disc Medicine (IRON) to $115 from $83 and keeps a Buy rating on the shares after the company announced topline results from the…
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management ...
Disc Medicine rises 34.0%
Disc Medicine (IRON) is up 34.0%, or $19.32 to $76.16.
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Disc Medicine stock gained on Monday following new clinical trial results that met primary and secondary endpoints.
Disc Medicine price target raised to $130 from $100 at LifeSci Capital
LifeSci Capital raised the firm’s price target on Disc Medicine (IRON) to $130 from $100 and keeps an Outperform rating on the shares. The company announced positive topline results from…
Disc Medicine price target raised to $110 from $100 at Wedbush
Wedbush raised the firm’s price target on Disc Medicine (IRON) to $110 from $100 and keeps an Outperform rating on the shares.
Disc Medicine price target raised to $120 from $100 at BMO Capital
BMO Capital analyst Evan David Seigerman raised the firm’s price target on Disc Medicine (IRON) to $120 from $100 and keeps an Outperform rating on the shares. The firm says…
Disc Medicine rises 29.4%
Disc Medicine (IRON) is up 29.4%, or $16.73 to $73.57.
Disc Medicine's rare disease drug succeeds in late-stage trial
Disc Medicine said on Monday its experimental pill for a rare disease that causes extreme pain from sunlight met all of its main and secondary goals in a late-stage trial, sending its shares surging...
Disc Medicine Transcript: Study result
APOLLO met both co-primary and all secondary endpoints, with lower PpIX, more pain-free time in light and fewer phototoxic reactions. Safety was consistent with prior studies; NDA resubmission is planned by year-end 2026, with an FDA decision anticipated by mid-2027.
Disc Medicine Press release: Study result
Disc Medicine issued a press release on October 19, 2026, disclosing material business information to investors.
Disc Medicine Slides: Study result
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on October 19, 2026.
Disc Medicine reports APOLLO trial meets primary, secondary endpoints
Disc Medicine (IRON) announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyri, or EPP, including X-linked protoporphyria, or XLP. The trial met all its pri...
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protopor...
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...